source
- AstraZeneca reports positive late-stage results for Tagrisso-Orpathys combo and Enhertu in lung cancerAstraZeneca said on Monday that two separate late-stage studies in lung cancer have produced positive outcomes. One study evaluated a combination of the tyrosine-kinase inhibitor Tagrisso with the…
- Eli Lilly signs up to $370 million ion-channel collaboration with OmniAbEli Lilly announced a collaboration and licensing agreement with California-based drug discovery company OmniAb that will focus on ion-channel targets. The deal could see Lilly paying up to $370 m…